KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cost of Revenue (2022 - 2025)

Historic Cost of Revenue for Recursion Pharmaceuticals (RXRX) over the last 4 years, with Q3 2025 value amounting to $14.7 million.

  • Recursion Pharmaceuticals' Cost of Revenue rose 2159.12% to $14.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.5 million, marking a year-over-year increase of 6413.7%. This contributed to the annual value of $45.2 million for FY2024, which is 622.49% up from last year.
  • Recursion Pharmaceuticals' Cost of Revenue amounted to $14.7 million in Q3 2025, which was up 2159.12% from $20.2 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Cost of Revenue ranged from a high of $21.8 million in Q1 2025 and a low of $7.8 million during Q1 2022
  • Over the past 4 years, Recursion Pharmaceuticals' median Cost of Revenue value was $12.1 million (recorded in 2024), while the average stood at $12.9 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first crashed by 3405.5% in 2023, then skyrocketed by 11916.51% in 2025.
  • Quarter analysis of 4 years shows Recursion Pharmaceuticals' Cost of Revenue stood at $10.8 million in 2022, then dropped by 8.85% to $9.9 million in 2023, then increased by 29.48% to $12.8 million in 2024, then grew by 14.8% to $14.7 million in 2025.
  • Its Cost of Revenue stands at $14.7 million for Q3 2025, versus $20.2 million for Q2 2025 and $21.8 million for Q1 2025.